Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing U-Factor Life Science Co., Ltd. is a clinical-stage biotechnology company specializing in the development of next-generation cell therapies and regenerative medicine. The company focuses on the research and industrialization of Natural Killer (NK) cell-based immunotherapies and mesenchymal stem cell (MSC) technologies. Utilizing its proprietary U-NK platform, U-Factor enables the large-scale expansion and activation of high-purity, off-the-shelf NK cells for oncology applications. Their pipeline includes CAR-NK candidates targeting solid tumors and hematological malignancies, alongside MSC-based treatments for chronic degenerative diseases. U-Factor is positioned as a leader in the Chinese cellular immunotherapy sector, integrating advanced genetic engineering with robust manufacturing capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on U-Factor Life Science.